Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
1305 East Houston Street , San Antonio, TX, 78205, US
As the number of new companies in biopharma continues to grow, so does their demand for outsourcing at every level of biopharmaceutical development.
Released By Scorpius BioManufacturing
A global pandemic magnified the need for more biologics manufacturing capacity. Capacity, however, isn’t the whole story.
What is a culture of quality, and how do you know if a biologics CDMO can earnestly make this claim?
Samir Lakhashe, Director, Bioanalytical Sciences, discusses assay categorization, the company's growing toolbox, predictions for the future, and more.
The demand for biologic drugs continues to grow at a steady 12–14% annually.
100 subject matter experts were surveyed from smaller biotech innovators to gain insight into the dynamics and drivers of the current biologics market.
Clinical manufacturing of cGMP-compliant mammalian cell culture processes is a complex and resource-intensive effort that presents several challenges.
Biologics process development is an active undertaking that seeks continuous improvement along the entire length of the drug development timeline.
A look at a CDMO’s value throughout a monoclonal antibody (mAb) therapeutic's lifecycle.
The value biologics CDMOs provide their innovator customers has changed radically in recent years, presenting new questions that must be answered.
The biologics CDMO selected for a given product or program is critical to an innovator’s ability to deliver a drug product safely, on time, and on budget.
When selecting a biologics CDMO partner—whether you need mammalian or microbial capabilities—the decision-making process follows a similar process.
Why Fina Biosolutions partnered with Scorpius Biomanufacturing for cGMP production of Ecocrm® (CRM197)
While crafting a RFP to capture the information innovators need to select a CDMO partner has always been critical; it has grown increasingly complicated.
The partnership includes recovery and downstream process optimization, analytical method implementation and phase-appropriate validation, and more.
Flexible, responsive, customized services for taking a program from R&D into the clinic, using American facilities and American sourced materials and equipment.
Delivering consistent and scalable mammalian-derived products, Scorpius uses its American facilities to advance your drug from R&D to the clinic and beyond.
Scorpius’ team has extensive experience in E. coli microbial biomanufacturing, including hard-to-work-with inclusion bodies.
Utilizing American-made equipment and reagents, Scorpius develops custom assays to profile your molecule and test your clinical trial samples.
Process development & cGMP contract manufacturing for biologics and cell therapies.
All three facilities are located in Wuxi, China, and combine to provide end-to-end CRDMO services.
By: Patrick Lavery
How AI, 3DP & Agile Manufacturing Are Reshaping Pharma & Patient Care.
Released By Aprecia Pharmaceuticals
New GMP facility strengthens integrated protein therapeutic development and manufacturing capabilities.
By: Charlie Sternberg
J.TRAIN is designed to enable biopharma companies to increase capacity and manufacture biologics at reduced costs and improved productivity.
There is still trial and error, but AI is now demonstrably impacting CDMOs across the entire value chain.
The company will also soon be expanding its New Jersey manufacturing facility.
Facility is fully operational, with GMP qualification protocols actively underway.
By: Kristin Brooks
Investment in Modersys will be focused on the life sciences sectors to support faster product investment decisions and longer-term customer partnerships.
Companies aim to de-risk and accelerate development for clients by combining capabilities.
A closer look at the chemistry, containment, purification, peptide manufacturing, and sustainability challenges shaping modern API development.
Released By Veranova
New 128,000-sq.-ft. facility in Andover will support the development and commercialization of ADVC001 and its pipeline of Lead-212 targeted alpha therapies.
Sponsored By ProBio CDMO
Biosafety testing facility earns fourth EMA GMP certificate with zero critical findings.
The freezing and thawing platform is designed for maximizing process consistency and product quality for high-value biologics.
Sponsored By Adare Pharma Solutions
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
